LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Regulus Therapeutics Inc

Chiusa

8.21 1.36

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.01

Massimo

8.27

Metriche Chiave

By Trading Economics

Entrata

3.2M

-9.6M

Vendite

340K

340K

EPS

-0.15

Margine di Profitto

-2,833.529

Dipendenti

34

EBITDA

2.2M

-11M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+8.64% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

315M

550M

Apertura precedente

6.85

Chiusura precedente

8.21

Regulus Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 apr 2025, 16:35 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 apr 2025, 11:55 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 apr 2025, 11:54 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire Regulus in $1.7 Billion Deal

27 mag 2025, 12:04 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Novartis Will Offer $7.00 in Cash Per Share

27 mag 2025, 12:01 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Offer Will Expire on June 24

27 mag 2025, 12:00 UTC

Acquisizioni, Fusioni, Takeovers

Novartis Will Offer $0.001 Per Share

27 mag 2025, 11:59 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Offer Is to Acquire All Outstanding Shares of Regulus Therapeutics's Common Stock

27 mag 2025, 11:59 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Redwood Merger Sub Inc. Is an Indirect Wholly Owned Subsidiary of Novartis

27 mag 2025, 11:58 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Redwood Merger Sub Inc. Has Commenced a Tender Offer

27 mag 2025, 11:57 UTC

Acquisizioni, Fusioni, Takeovers

Novartis Announces Commencement of Tender Offer to Buy Regulus Therapeutics

30 apr 2025, 11:40 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 apr 2025, 11:39 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire Regulus in $1.7B Deal

30 apr 2025, 11:16 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 apr 2025, 11:15 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 apr 2025, 11:14 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 apr 2025, 11:13 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Buy Regulus Therapeutics

Confronto tra pari

Modifica del prezzo

Regulus Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

8.64% in crescita

Previsioni per 12 mesi

Media 8.8 USD  8.64%

Alto 11 USD

Basso 7 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Regulus Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

1

Acquista

5

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.